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Abstract
Background—The relationship between alcohol intake and rectal cancer is uncertain
Objective—We sought to evaluate whether alcohol consumption is associated with distal
colorectal cancer and rectal cancer specifically.
Design—Data on alcohol intake were examined from the North Carolina Colon Cancer Study, a
population-based case control study of distal colorectal cancer.
Setting—33 counties in the central and eastern part of North Carolina
Patients—Cases had adenocarcinoma of the rectum, rectosigmoid, and sigmoid colon. Controls
were frequency-matched on age, race, and gender.
Interventions—Demographic and dietary intake data were collected using a validated
questionnaire.
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Main outcome measures—Logistic regression was used to estimate odds ratios for the
relationship between alcohol consumption and distal colorectal cancer.
Results—1,033 cases and 1,011 controls participated. The odds ratio for rectal cancer comparing
any vs. no alcohol intake was 0.73 (95% confidence interval 0.60, 0.90), adjusted for age, gender,
race, smoking status, obesity, education, red meat intake, use of non-steroidal anti-inflammatory
medications and family history of colorectal cancer. The odds ratio for moderate alcohol (≤14
grams/day) was 0.66 (0.53, 0.82), while the odds ratio for heavy alcohol (>14 grams/day) was 0.93
(0.70, 1.23). Moderate beer and wine intakes were also inversely associated with distal colorectal
cancer: odds ratios 0.76 (0.60, 0.96) and 0.69 (0.56, 0.86) respectively.
Limitations—This was a retrospective, observational study. Residual confounding is possible.
Conclusions—In this study, moderate alcohol intake (especially wine) was inversely associated
with distal colorectal cancer.
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Introduction
Colorectal cancer (CRC) ranks 3rd in both incidence and cancer mortality among men and
women in the US, with roughly 150,000 people diagnosed and 50,000 attributable deaths
each year.1 Rectal cancer accounts for a substantial portion of all CRC, approximately 30%
of cases.2 Optimal treatment for rectal cancer requires coordinated, multi-specialty care, and
is associated with higher with healthcare utilization and costs compared to colon cancer.3 In
addition to differences in management, rectal cancer and colon cancer also have different
risk factor profiles.4, 5
Alcohol is a potentially modifiable risk factor that has been linked to multiple cancers of the
gastrointestinal tract including oropharyngeal and squamous esophageal cancer.6–10 With
respect to CRC, the evidence is conflicting. Previous studies have reported a weak positive
association between alcohol and CRC, especially for higher alcohol intakes.11, 12 Some
studies, however suggest an inverse relationship between alcohol and CRC, especially
wine.13, 14 The effect of beer intake on CRC is uncertain. Few studies focus on the
relationship between alcohol and rectal cancer specifically. Furthermore, many studies of
this association have taken place in European countries, where drinking patterns and social
determinants of alcohol consumption may differ from the US.
Utilizing data from the North Carolina Colon Cancer Study, a large population-based case-
control study, we aimed to determine the association between alcohol intake and the risk of
distal CRC. We were particularly interested in the effect of moderate alcohol intake and the
effects of different beverages (beer, wine, and liquor) on risk of rectal cancer.
Materials and Methods
Study design & population
The North Carolina Colon Cancer Study-Phase II (NCCCS-II) was a population-based case-
control study of incident distal large bowel cancer (rectal, recto-sigmoid, or sigmoid cancer)
in 33 counties in the central and eastern part of North Carolina.15 These counties included
urban, suburban, and rural areas and a diverse socioeconomic population. Study data were
collected by trained nurse interviewers during in-person interviews. In order to confirm the
diagnosis of invasive adenocarcinoma of sigmoid, rectosigmoid, or rectum, pathology
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reports were obtained and reviewed by the study pathologist for each case. The study was
designed and reported in accordance with the STROBE guidelines 16.
Identification of cases and controls
Participants (cases and controls) were eligible for the study if they were residents of the
selected counties, aged between 40 and 80 years, had a North Carolina driver’s license or
identification card, were able to complete an interview in English, and were not deaf or hard
of hearing, too ill to be interviewed, legally incompetent or currently incarcerated.
A total of 1831 potentially eligible patients with a first diagnosis of invasive
adenocarcinoma in sigmoid, rectosigmoid, and rectum were identified through the rapid case
ascertainment system of the North Carolina Central Cancer Registry between May 2001 and
September 2006.17 Of the 1,831 potentially eligible cases identified, 57 (3%) were excluded
for physician refusal, and 357 (19%) were found ineligible. Of the remaining 1,417 eligible
cases, 118 (8%) were not able to be contacted, 242 (17%) refused to participate, and 1,058
(75%) completed an in-person interview. Subsequently, 25 cases were excluded as they had
no data on alcohol intake, the exposure of interest.
Using a randomized recruitment technique,18 controls without a previous diagnosis of CRC
were randomly selected from North Carolina Division of Motor Vehicle records (for
controls age <65) or from Health Care Financing Administration (HCFA) records (for
controls age ≥65), based on sampling probabilities within blocks defined by sex, race, and
5-year age group. African Americans were oversampled in order to enhance their
proportion. A total of 2,345 subjects were initially identified as eligible controls, but 518
(22%) were later determined to be ineligible according to the above criteria (e.g. they did not
reside in the 33 county study area, etc.). Of the 1,827 remaining eligible controls, 325 (18%)
were not able to be contacted, and 483 (26%) refused to participate. A total of 1,019 (56% of
eligible controls) completed an interview. Subsequently, 8 controls were excluded because
they had no data on alcohol intake. This study was approved by the Institutional Review
Board of the University of North Carolina, and all subjects provided written informed
consent prior to participation.
Assessment of main exposure and covariates of interest
Information on alcohol intake was obtained during the interview. Participants were asked
whether they drank beer, wine, or liquor, and the frequency and amount of consumption 1
year prior to diagnosis (cases) or at the time of interview (controls). From responses to these
questions, consumption of beer (ounces/day), wine (ounces/day) and liquor (shots/day) were
calculated. Alcohol intake (grams (g)/day) was also determined from these questions.
Alcoholic beverage consumption was subsequently categorized into none, moderate, and
heavy intake based on accepted definitions.19 Non-beverage alcohol consumption (e.g. trace
amounts of alcohol used in cooking) was disregarded.
Data on potential confounders including non-steroidal anti-inflammatory drug (NSAID) use,
physical activity, red meat intake, smoking, and family history of colorectal cancer were
also obtained in the interview. In addition to age, race, and sex, demographic information
such as education, household income, and insurance status was also collected. All
participants were asked their weight 1 year prior to diagnosis (case) or interview (control) in
order to calculate body mass index from a weight that was unaffected by the cancer
diagnosis or treatment. Physical activity was assessed via a validated 7 day physical activity
recall questionnaire.20, 21 Dietary intake was assessed via a validated Diet History
Questionnaire 22, 23. Daily intakes of nutrients and other food components (including
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alcohol) were calculated with DietCalc software obtained from the National Cancer Institute
(http://riskfactor.cancer.gov/DHQ/dietcalc).
Statistical analysis
Bivariate analysis of exposure variables was performed using chi-squared tests. Alcohol
intake was examined using variables that accounted for different levels of intake, beverage
type, and combination of beverages consumed. All covariates were assessed for confounding
and effect measure modification. Because folate intake was felt to be a causal intermediate
on the pathway from alcohol to CRC, it was not included as a covariate in multivariate
analyses.24 Multivariate logistic regression modeling was performed to estimate odds ratios
(OR) and 95% confidence intervals (CI) for the association between alcohol intake and
distal CRC. All logistic regression models included indicator variables for the matching
strata (determined by sex, age and race) as well as an offset term to adjust for sampling
probability.18, 25
To determine which covariates should be included in the final multivariable models, we
constructed a full model with all potential confounders, and assessed the change in beta
coefficients for those with any vs. no alcohol intake in relation to distal CRC when
covariates were removed using backwards elimination with a threshold of <10% change in
beta coefficients and a likelihood ratio test p value of >0.10. The final model contained the
exposure (alcohol intake), educational level, smoking status, obesity, family history of colon
cancer, red meat consumption and NSAID use.
We also constructed logistic regression models for each exposure subtype of interest (e.g.
beer, wine, or spirits), and with a categorical exposure variable accounting for different
combinations of beverages consumed. Finally, polytomous regression (using the same
exposure variables) was subsequently used to evaluate whether the observed effects were
similar amongst those with cancer of the rectum, and rectosigmoid and sigmoid colon.
Because polytomous models cannot incorporate weights, the offset term was not included




The final study population included 1,033 cases and 1,011 controls. Cases and controls
differed significantly by age, race, red meat intake, NSAID use, education level, insurance
status, and household income (Table 1). Significant differences also existed between cases
and controls with respect to overall alcohol intake and quantities of specific alcoholic
beverages consumed. In general, cases had a higher proportion of non drinkers and a lower
proportion of moderate drinkers for beer, wine, and liquor (Table 2).
Primary analyses
The OR for distal CRC for those with any alcohol intake compared to nondrinkers was 0.73
(95% CI 0.60, 0.90). We further analyzed the effect of different levels of alcohol
consumption. The adjusted OR for distal CRC associated with moderate alcohol intake was
0.66 (95% CI 0.53, 0.82), indicating that the odds of distal CRC were decreased for
moderate alcohol users. There was no statistically significant association between heavy
alcohol use and distal CRC (Table 3).
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After adjusting for confounders, moderate beer intake was associated with an OR for distal
CRC of 0.76 (95% CI 0.60, 0.96). Moderate wine intake was also inversely related to distal
CRC: OR 0.69 (95% CI 0.56, 0.86). Neither heavy beer nor heavy wine intake were
significantly associated with distal CRC. There were no statistically significant associations
between liquor intake and CRC, though the highest level of liquor consumption (>1 shot/
day) did appear to be associated with an elevated risk of CRC: OR 1.46 (95% CI 0.92, 2.36)
(Table 3).
Because of overlapping consumption of different alcoholic beverages, we sought to estimate
the effects of both isolated consumption of each beverage type, and different combinations
of beverages consumed. Wine intake, whenever it was included in beverage combinations,
was associated with the lowest OR of CRC (for wine only: OR 0.64 (95% CI 0.45, 0.93), for
wine and beer: OR 0.60 (95% CI 0.41, 0.88); and for wine, beer and liquor: 0.74 (95% CI
0.54, 1.00)) (Figure 1).
Effect of race, sex, and smoking status
When stratified by race, the OR for distal CRC associated with moderate alcohol intakes
was similar for Blacks and non-Blacks. Similarly, males and females had similar odds of
distal CRC associated with moderate intake. When stratified by smoking status, never
smokers had the lowest ORs associated with moderate wine and liquor consumption, while
current smokers had the highest ORs, but this OR heterogeneity was not statistically
significant (p = 0.6) (Table 4).
Site of cancer
Because this study included cases of distal CRC including cancers of the rectum,
rectosigmoid and sigmoid colon, we sought to estimate the ORs for each site specifically.
For moderate overall alcohol intake, the OR of rectal cancer specifically was 0.69 (95% CI
0.51, 0.93). For moderate wine intake, the OR for rectal cancer was similar: 0.69 (95% CI
0.51, 0.93) (Table 5).
Discussion
In this case control study, we found that alcohol use and especially wine intake was
inversely associated with distal colorectal cancer. This effect was consistent for cancers of
the rectum, recto-sigmoid and sigmoid colon, was not modified by age, race, sex, or
smoking status, and persisted after accounting for multiple potential confounding factors.
The protective effect appeared confined primarily to the moderate consumption strata across
alcohol types.
Some previous studies have shown a positive association between alcohol intake
(particularly heavy alcohol use) and rectal cancer, generally of fairly low magnitude. A
meta-analysis of 27 studies relating consumption of alcoholic beverages to risk of colorectal
cancer found a weak positive association for consumption of 2 or more alcoholic drinks (24
g) daily and rectal cancer (relative risk (RR) 1.10 (95% CI 1.02, 1.18)).12 A pooled analysis
of 8 cohort studies addressing this topic found that only high alcohol intakes (30 to <45 g/
day and ≥45 g/day) were significantly associated with increased risk of rectal cancer: RR
1.42 (95% CI 1.07, 1.88) and 1.49 (95% CI 1.04, 2.12) respectively.11 An analysis from the
multicenter European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
study reported an elevated risk of rectal cancer only for those with very high average
lifetime alcohol intakes: hazard ratio (HR) for those consuming (>60g/day) compared to the
lowest level of consumption was 2.59 (95% CI 1.62, 4.13). However, other studies have
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reported both null and inverse associations between alcohol consumption and CRC.13, 14, 26
Nevertheless, previous reports that heavy alcohol consumption is associated with increased
risk of CRC are not necessarily inconsistent with our findings.
We focused on moderate intake but also found evidence that heavy intake of alcohol may be
associated with increased risk of distal CRC. Heavy alcohol consumption was relatively rare
in our sample; 109 participants (5.3%) had alcohol intakes ≥ 45grams/day and 70
participants (3.4%) had alcohol intakes >60 g/day. Given the small numbers of heavy
alcohol consumers in our study, it is certainly possible that higher levels of alcohol
consumption are associated with an elevated risk of CRC. Indeed, in this study heavy beer
and liquor intakes were associated with ORs greater than 1, though they were not
statistically significant. This finding points to the possibility that there may be a “J-shaped”
dose-response curve for alcohol and CRC, in which moderate intakes are associated with
reduced risk of CRC, but the risk increases for those with heavy use as others have
postulated.13 Our findings may also differ somewhat from previous studies because of
changes in folate intake over time. Since alcohol interferes with folate metabolism and folate
has been shown to have a protective effect for CRC,27–29 changes in folate intake could
impact the total effect of alcohol on rectal cancer. Indeed, some studies have suggested that
adequate folate is a necessary precursor for a beneficial effect of alcohol in CRC.27, 30 Since
1996, the US Food and Drug Administration has required the addition of folic acid to
enriched breads, cereals, flours, corn meals, pastas, rice, and other grain products,31 which
may be one reason why some American studies conducted prior to the late 1990s found that
alcohol was associated with an elevated risk of CRC.
Several studies have reported either a null or an inverse association between wine
consumption and CRC, particularly with moderate wine intake.12–14, 32, 33 In a study of
41,837 post-menopausal women in the US, wine consumption was found to be inversely
associated with distal colon cancer: RR 0.64 (95% CI 0.40, 0.98).14 A Danish cohort study
found that wine consumption lowered the risk of rectal cancer, even in combination with
other alcoholic beverages.33 In a recent analysis from a British cohort study involving
25,639 participants, daily consumption of 1 or more glasses of wine was associated with a
decreased risk of CRC (HR 0.61 (95% CI 0.40, 0.94).13 Interestingly, wine intake has also
been demonstrated to be inversely associated with other gastrointestinal cancers, namely
gastric34 and esophageal adenocarcinoma.8
Apart from its relationship to cancer, moderate alcohol intake is associated with a variety of
salutatory effects such as protection from coronary heart disease,35, 36 stroke,37, 38
diabetes,39 dementia,36 and even reduced overall mortality.40 The biologic mechanism by
which alcohol may mitigate the risk of cancer is unknown, but may be related to antioxidant
properties. Wine in particular has antioxidant and antithrombotic properties related to its
flavonoid and phenolic components.41 One of these compounds, resveratrol, has been shown
to have cancer chemopreventive effects.42
This study has important strengths. We used a validated questionnaire for measurement of
exposure and covariates of interest. The outcome (distal CRC) was determined via a cancer
registry and was independently verified by the study team, making measurement error
unlikely. In comparison with other published studies on this topic, we enrolled a relatively
large number of CRC cases, and thus our statistical power allowed for more precise
estimates. The population-based sampling of this study avoids the selection bias that occurs
when cases are drawn from a single hospital. African Americans represented 21% of our
study population (because of over-sampling), which is substantially higher than other studies
on this topic. We were able to evaluate a large number of covariates for possible
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confounding, and all recognized important confounders of the relationship between alcohol
and CRC were controlled for in our multivariate analysis.
The limitations of this study are primarily related to potential misclassification of the
exposure. Alcohol intake was self-reported as recorded on the nurse-administered study
questionnaire. It is well known that self-reported alcohol intake is subject to under or
misreporting, and as with all retrospective studies, there is potential for recall bias. Because
of the manner in which the study questionnaire was structured, we obtained average daily
consumption, and could not account for patterns of use such as binge drinking or changes in
drinking patterns over time, or for lifetime alcohol consumption. Furthermore, the
definitions of moderate and heavy alcohol use may not apply equally to all participants
because of body weight and/or genetic differences, though we did adjust for elevated body
mass index in our analyses. Another issue with all observational trials of alcohol intake
relates to the fact that abstainers may be systematically different from non-abstainers. The
nondrinker category may contain former drinkers including recovered alcoholics, and those
who stop drinking due to illness or concern for medication interactions. Moderate drinking
also may be a marker of higher socioeconomic status, a healthier lifestyle, or both. For this
reason, we evaluated several different measures of socioeconomic status for confounding
(education level, insurance status, and income). Nevertheless, we cannot exclude the
possibility that drinking in moderation is so tightly coupled to other cancer-protective
behaviors that multivariate analysis was unable to completely isolate the effect of alcohol
intake alone, and that residual confounding exists. Though we did not find statistically-
significant results in some smaller subgroups (e.g. heavy drinkers of wine and liquor) this
may be due to a lack of statistical power, and thus these results should be interpreted with
caution.
In conclusion, moderate alcohol intake, especially wine, was inversely associated with distal
colorectal cancer in this population-based case-control study. These results should not be
interpreted as an endorsement of alcohol, because excessive alcohol consumption has been
clearly linked to other health problems such as accidents and injuries,43 teratogenicity,44
cardiomyopathy,45 pancreatitis,46 liver disease,47 and premature death,48 and there are some
individuals for whom no amount of alcohol is safe (e.g. people with alcoholism or cirrhosis).
Nevertheless, our findings add to the growing body of literature suggesting that drinking
alcohol in moderation may have a beneficial role for some cancers, including rectal cancer.
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Odds ratio of distal colorectal cancer by type and combination of alcohol consumed,
demonstrating consistent inverse relationship with wine consumption vs. other beverage
types.
Odds ratios obtained via logistic regression, adjusted for age, sex, race, red meat intake,
NSAID use, family history of CRC, obesity, smoking status, and education level. CRC:
colorectal cancer; NSAID: non-steroidal anti-inflammatory drug.
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Table 1





Covariate n (%) or mean ± SD n (%) or mean ± SD
Age (in years)†
    40–49 149 (14.4) 101 (10.0)
    50–59 285 (27.6) 239 (23.6)
    60–69 313 (30.3) 324 (32.1)
    70–79 286 (27.7) 347 (34.3)
Sex
    Female 449 (43.5) 414 (41.0)
Race‡
    White 747 (73.7) 818 (82.3)
    Black 257 (25.4) 169 (17.0)
    Other 9 (0.9) 7 (0.7)
Positive family history of CRC§ 128 (12.7) 100 (10.1)
Smoking status
    Never smoked 377 (37.5) 379 (38.5)
    Former smoker 447 (44.5) 463 (47.1)
    Current smoker 181 (18.0) 142 (14.4)
Obese 320 (33.2) 306 (31.7)
Physical activity (met-min/day) 2249.2 ± 662.2 2162.3 ± 487.1
Total folate intake
    <400 mcg/day 247 (23.9) 233 (23.1)
    ≥400 mcg/day 786 (76.1) 778 (76.9)
Red meat intake (grams/day) 83.6 ± 69.4 73.7 ± 58.2
NSAID use
    <15 uses/month 684 (68.0) 579 (58.5)
    ≥15 uses/month 322 (32.0) 410 (41.5)
Education
    ≤High school graduate 540 (53.7) 422 (42.6)
    Some college 244 (24.3) 257 (26.0)
    ≥College graduate 222 (22.1) 311 (31.4)
Uninsured 52 (5.2) 27 (2.7)
Household income
    <$25,000/year 337 (35.7) 281 (30.2)
    ≥$25,000/year 607 (64.3) 649 (69.8)
†
Age at diagnosis for cases, or at time of interview for controls.
‡
Self-reported race differs slightly from the administrative race definition used for matching.
§
Family history of colorectal cancer in a 1st degree relative.
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NSAID: non-steroidal anti-inflammatory drug
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Table 2





Exposure variables n (%) n (%) p*
All alcohol <0.0001
    None 548 (53.1) 435 (43.0)
    Moderate (>0 & ≤14 g/day) 304 (29.4) 390 (38.6)
    Heavy (>14 g/day) 181 (17.5) 186 (18.4)
Beer intake 0.001
    None 689 (66.7) 620 (61.4)
    Moderate (>0 & ≤12 oz/day) 260 (25.2) 325 (32.2)
    Heavy (>12 oz/day) 84 (8.1) 65 (6.4)
Wine intake <0.0001
    None 726 (70.4) 592 (58.6)
    Moderate (>0 & ≤6 oz/day) 271 (26.3) 374 (37.0)
    Heavy (>6 oz/day) 35 (3.4) 45 (4.5)
Liquor intake 0.01
    None 764 (74.0) 692 (68.5)
    Moderate (>0 & ≤1 shot/day) 222 (21.5) 275 (27.2)
    Heavy (>1 shot/day) 47 (4.6) 44 (4.4)
*
p values determined via chi-squared tests.
g: grams; oz: ounces
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Table 3
Unadjusted and adjusted odds ratios for distal colorectal cancer by type of alcohol consumed*
Unadjusted Adjusted
Type of alcohol OR (95% CI) OR (95% CI)
All alcohol intake
    None 1.00 1.00
    Moderate (>0 & ≤14 g/day) 0.60 (0.49, 0.73) 0.66 (0.53, 0.82)
    Heavy (>14 g/day) 0.78 (0.61, 1.01) 0.93 (0.70, 1.23)
Beer intake
    None 1.00 1.00
    Moderate (>0 & ≤12 oz/day) 0.69 (0.56, 0.85) 0.76 (0.60, 0.96)
    Heavy (>12 oz/day) 1.14 (0.79, 1.64) 1.16 (0.79, 1.70)
Wine intake
    None 1.00 1.00
    Moderate (>0 & ≤6 oz/day) 0.60 (0.49, 0.73) 0.69 (0.56, 0.86)
    Heavy (>6 oz/day) 0.68 (0.43, 1.09) 0.83 (0.50, 1.36)
Liquor intake
    None 1.00 1.00
    Moderate (>0 & ≤1 shot/day) 0.72 (0.58, 0.89) 0.83 (0.66, 1.05)
    Heavy (>1 shot/day) 1.11 (0.72, 1.72) 1.46 (0.92, 2.36)
*
Regardless of other alcoholic beverage consumption. ORs obtained via logistic regression, adjusted for age, sex, race, red meat intake, NSAID
use, family history of colorectal cancer, obesity, smoking status, and education level.
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Table 4
Adjusted odds ratios for distal colon cancer for moderate alcohol, beer, wine, and liquor consumption,
stratified by race, sex, and smoking status
Moderate alcohol Moderate beer Moderate wine Moderate liquor
Strata of covariate OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Race
    Black 0.62 (0.38, 1.02) 0.63 (0.37, 1.06) 0.75 (0.45, 1.27) 0.70 (0.40, 1.22)
    Nonblack 0.67 (0.53, 0.86) 0.81 (0.63, 1.04) 0.68 (0.54, 0.87) 0.86 (0.67, 1.11)
Sex
    Female 0.59 (0.43, 0.82) 0.80 (0.55, 1.17) 0.65 (0.47, 0.90) 0.74 (0.50, 1.08)
    Male 0.71 (0.53, 0.95) 0.74 (0.56, 0.98) 0.73 (0.55, 0.96) 0.89 (0.67, 1.18)
Smoking
    Never 0.60 (0.43, 0.85) 0.77 (0.53, 1.13) 0.55 (0.39, 0.78) 0.68 (0.45, 1.01)
    Former 0.71 (0.52, 0.99) 0.80 (0.58, 1.09 0.76 (0.55, 1.03) 0.89 (0.64, 1.24)
    Current 0.66 (0.38, 1.15) 0.65 (0.38, 1.11) 0.92 (0.55, 1.56) 1.02 (0.60, 1.76)
ORs obtained via logistic regression, adjusted for age, sex, race, red meat intake, NSAID use, family history of colorectal cancer, obesity, smoking
status, and education level. P values for likelihood ratio tests for models with interaction terms for race, sex, and smoking status all>0.10 indicating
lack of strong effect measure modification.
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Table 5
Adjusted odds ratios for cancer of the rectum, rectosigmoid and sigmoid cancer for moderate alcohol, beer,
wine, and liquor consumption.
Moderate alcohol Moderate beer Moderate wine Moderate liquor
Cancer site OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Rectum (n=386) 0.69 (0.51, 0.93) 0.79 (0.58, 1.08) 0.69 (0.51, 0.93) 0.77 (0.55, 1.06)
Rectosigmoid (n=166) 0.55 (0.36, 0.84) 0.64 (0.41, 1.00) 0.66 (0.44, 1.01) 0.84 (0.54, 1.30)
Sigmoid (n=468) 0.68 (0.51, 0.91) 0.77 (0.57, 1.03) 0.70 (0.53, 0.93) 0.88 (0.66, 1.19)
ORs obtained via polytomous logistic regression, adjusted for age, sex, race, red meat intake, NSAID use, family history of CRC, obesity, smoking
status, and education level. Cases with site recorded as “colon not otherwise specified” not included in this analysis (n=13).
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